BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O. The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints? Am J Respir Crit Care Med 2018;197:860-8. [PMID: 29256625 DOI: 10.1164/rccm.201709-1840PP] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med 2020;201:707-17. [PMID: 31765604 DOI: 10.1164/rccm.201908-1640OC] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
2 Arevalo C, White R, Lachant D. Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension. Respiratory Medicine Case Reports 2022. [DOI: 10.1016/j.rmcr.2022.101646] [Reference Citation Analysis]
3 Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. J Investig Med 2021;69:1270-80. [PMID: 34580123 DOI: 10.1136/jim-2021-002027] [Reference Citation Analysis]
4 Wilson M, Keeley J, Kingman M, Wang J, Rogers F. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ 2020;10:2045894020950186. [PMID: 33062258 DOI: 10.1177/2045894020950186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, Charalampopoulos A, Sabroe I, Thompson AAR, Billings CG, Hamilton N, Baster K, Laud PJ, Hickey PM, Middleton J, Armstrong IJ, Hurdman JA, Lawrie A, Rothman AMK, Wild JM, Condliffe R, Swift AJ, Kiely DG. Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2020;201:458-68. [PMID: 31647310 DOI: 10.1164/rccm.201909-1771OC] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 13.5] [Reference Citation Analysis]
6 Kaymaz C, Akbal OY, Hakgor A, Tokgoz HC, Tanyeri S. Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension. Pulm Circ 2018;8:2045894018780522. [PMID: 29767575 DOI: 10.1177/2045894018780522] [Reference Citation Analysis]
7 Pi H, Carlson SD, Barros LM, Hogl L, Kirkpatrick JN, Nolley S, Ralph DD, Rayner SG, Leary PJ. Risk Prediction and Right Ventricular Dilation in a Single‐Institution Pulmonary Arterial Hypertension Cohort. JAHA. [DOI: 10.1161/jaha.122.025521] [Reference Citation Analysis]
8 Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, Sitbon O, Zamanian RT, Hemnes AR, Cravets M, Bruey JM, Roscigno R, Mottola D, Elman E, Zisman LS, Ghofrani HA. TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulm Circ 2021;11:20458940211057071. [PMID: 34790348 DOI: 10.1177/20458940211057071] [Reference Citation Analysis]
9 Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung 2020;198:65-86. [PMID: 31722043 DOI: 10.1007/s00408-019-00289-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz H, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth H, Held M, Dumitrescu D, Tsangaris I, Vonk-noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt K, Rosenkranz S, Lange TJ. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.03.011] [Reference Citation Analysis]
11 Weatherald J, Boucly A, Savale L, Jaïs X, Montani D, Humbert M, Sitbon O. Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance? Am J Respir Crit Care Med 2021;203:524-5. [PMID: 33105080 DOI: 10.1164/rccm.202009-3664LE] [Reference Citation Analysis]
12 Grignola JC, Domingo E, López-Meseguer M, Trujillo P, Bravo C, Pérez-Hoyos S, Roman A. Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension. Front Physiol 2021;12:631326. [PMID: 34012405 DOI: 10.3389/fphys.2021.631326] [Reference Citation Analysis]
13 Humbert M, Lau EMT. Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective. Am J Respir Crit Care Med 2021;203:675-7. [PMID: 33357026 DOI: 10.1164/rccm.202012-4350ED] [Reference Citation Analysis]
14 Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, Elliott CG, Farber HW. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest 2021;159:337-46. [PMID: 32882243 DOI: 10.1016/j.chest.2020.08.2069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
15 Hwalek A, Rosenheck JP, Whitson BA. Lung transplantation for pulmonary hypertension. J Thorac Dis 2021;13:6708-16. [PMID: 34992846 DOI: 10.21037/jtd-2021-20] [Reference Citation Analysis]
16 Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, Sitbon O. Riociguat: Clinical research and evolving role in therapy. Br J Clin Pharmacol 2021;87:2645-62. [PMID: 33242341 DOI: 10.1111/bcp.14676] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J 2019;53:1801908. [PMID: 30545975 DOI: 10.1183/13993003.01908-2018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 25.0] [Reference Citation Analysis]
18 Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, Hoeper MM. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;53:1802004. [PMID: 30923187 DOI: 10.1183/13993003.02004-2018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
19 Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Curr Hypertens Rep 2019;21:45. [PMID: 31025123 DOI: 10.1007/s11906-019-0950-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
20 Sahay S, Tonelli AR, Selej M, Watson Z, Benza RL. Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score. PLoS One 2020;15:e0241504. [PMID: 33175857 DOI: 10.1371/journal.pone.0241504] [Reference Citation Analysis]